Axsome Therapeutics (AXSM) to Release Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSMGet Free Report) is set to announce its earnings results before the market opens on Tuesday, February 20th. Analysts expect the company to announce earnings of ($1.21) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Axsome Therapeutics Stock Performance

Shares of Axsome Therapeutics stock opened at $97.64 on Tuesday. The company has a 50 day moving average of $82.41 and a 200-day moving average of $74.20. Axsome Therapeutics has a 1-year low of $53.71 and a 1-year high of $98.40. The company has a current ratio of 4.46, a quick ratio of 4.38 and a debt-to-equity ratio of 0.66. The company has a market cap of $4.62 billion, a PE ratio of -21.55 and a beta of 1.21.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on AXSM shares. Piper Sandler upped their price objective on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 16th. UBS Group started coverage on shares of Axsome Therapeutics in a research report on Tuesday, February 6th. They set a “buy” rating and a $111.00 price objective for the company. Citigroup started coverage on shares of Axsome Therapeutics in a research report on Wednesday, December 13th. They set a “buy” rating and a $125.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, December 26th. Finally, Royal Bank of Canada assumed coverage on shares of Axsome Therapeutics in a research report on Thursday, January 25th. They set an “outperform” rating and a $126.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $113.10.

Get Our Latest Stock Analysis on Axsome Therapeutics

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its stake in Axsome Therapeutics by 1.7% in the 1st quarter. AQR Capital Management LLC now owns 8,825 shares of the company’s stock worth $544,000 after purchasing an additional 148 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Axsome Therapeutics by 21.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 993 shares of the company’s stock valued at $71,000 after buying an additional 178 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Axsome Therapeutics by 1.7% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 14,627 shares of the company’s stock valued at $560,000 after buying an additional 245 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Axsome Therapeutics by 0.9% during the 4th quarter. Legal & General Group Plc now owns 27,011 shares of the company’s stock valued at $2,083,000 after acquiring an additional 250 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY boosted its position in shares of Axsome Therapeutics by 15.0% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 1,981 shares of the company’s stock valued at $153,000 after acquiring an additional 258 shares during the last quarter. 76.60% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Further Reading

Earnings History for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.